{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:12Z","timestamp":1786118952105,"version":"build-2736575974"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/psy.0b013e3181777190","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T21:03:15Z","timestamp":1212440595000},"page":"585-592","source":"Crossref","is-referenced-by-count":27,"title":["Psychopharmacology in HIV-Infected Patients"],"prefix":"10.1097","volume":"70","author":[{"given":"Martin J.","family":"Repetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Petitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20210213","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.58.8.721","article-title":"Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States.","volume":"58","author":"Bing","year":"2001","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 3","key":"R3-10-20210213","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1097\/00126334-200212153-00010","article-title":"Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.","volume":"31","author":"Starace","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-10-20210213","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/PSY.0b013e3181773bce","article-title":"Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions.","volume":"70","author":"Kalichman","year":"2008","journal-title":"Psychosom Med"},{"key":"R5-10-20210213","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PSY.0b013e3181777a5f","article-title":"Role of depression, stress, and trauma in HIV disease progression.","volume":"70","author":"Leserman","year":"2008","journal-title":"Psychosom Med"},{"key":"R6-10-20210213","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/QAI.0b013e31802c2f51","article-title":"Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.","volume":"44","author":"Pence","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-10-20210213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0163-8343(01)00174-8","article-title":"The effect of changes in depression on health related quality of life (HRQoL) in HIV infection.","volume":"24","author":"Elliott","year":"2002","journal-title":"Gen Hosp Psychiatry"},{"key":"R8-10-20210213","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.qai.0000147524.19122.fd","article-title":"Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients.","volume":"38","author":"Yun","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-10-20210213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/(SICI)1520-6394(1996)4:4<199::AID-DA6>3.0.CO;2-A","article-title":"Depression in the medically ill: management considerations.","volume":"4","author":"Evans","year":"1996","journal-title":"Depress Anxiety"},{"key":"R10-10-20210213","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1258\/0956462021925117","article-title":"Factors associated with adherence to antiretroviral medication in HIV-infected patients.","volume":"13","author":"Molassiotis","year":"2002","journal-title":"Int J STD AIDS"},{"key":"R11-10-20210213","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/ajp.151.2.221","article-title":"Factors associated with risk for HIV infection among chronic mentally ill adults.","volume":"151","author":"Kalichman","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R12-10-20210213","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/PSY.0b013e31817a5d30","article-title":"Effects of psychological interventions on neuroendocrine hormone regulation and immune status in HIV-positive persons: a review of randomized controlled trials.","volume":"70","author":"Carrico","year":"2008","journal-title":"Psychosom Med"},{"key":"R14-10-20210213","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/01.ALC.0000122103.74491.78","article-title":"Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems.","volume":"28","author":"Samet","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"R15-10-20210213","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/PSY.0b013e3181772157","article-title":"HIV prevention for injecting drug users: the first 25 years and counting.","volume":"70","author":"Des Jarlais","year":"2008","journal-title":"Psychosom Med"},{"key":"R16-10-20210213","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/appi.ajp.160.3.547","article-title":"Use of psychotropic medications among HIV-infected patients in the United States.","volume":"160","author":"Vitiello","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R17-10-20210213","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/JCP.0b013e31802f0dd1","article-title":"Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients.","volume":"27","author":"Dalessandro","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R18-10-20210213","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-8343(96)00172-7","article-title":"Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.","volume":"19","author":"Ferrando","year":"1997","journal-title":"Gen Hosp Psychiatry"},{"key":"R19-10-20210213","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1176\/ajp.151.4.516","article-title":"Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness.","volume":"151","author":"Rabkin","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R20-10-20210213","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1176\/ajp.155.3.367","article-title":"Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients.","volume":"155","author":"Elliott","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R21-10-20210213","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1176\/ajp.156.1.101","article-title":"Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.","volume":"156","author":"Rabkin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R22-10-20210213","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4088\/JCP.v59n0502","article-title":"Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.","volume":"59","author":"Zisook","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R23-10-20210213","first-page":"92","article-title":"Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.","volume":"55","author":"Rabkin","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R24-10-20210213","first-page":"433","article-title":"Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial.","volume":"55","author":"Rabkin","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R25-10-20210213","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4088\/JCP.v60n1104","article-title":"Antidepressant treatment of depression in HIV-seropositive women.","volume":"60","author":"Ferrando","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R26-10-20210213","first-page":"70","article-title":"Efficacy of paroxetine for treatment of depression in the context of HIV infection.","volume":"30","author":"Grassi","year":"1997","journal-title":"Pharmacotherapy"},{"key":"R27-10-20210213","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.psy.45.3.210","article-title":"Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study.","volume":"45","author":"Currier","year":"2004","journal-title":"Psychosomatics"},{"key":"R28-10-20210213","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1345\/aph.18240","article-title":"Significant interactions with new antiretrovirals and psychotropics.","volume":"33","author":"Tseng","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R29-10-20210213","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/00002030-200107060-00010","article-title":"Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine.","volume":"15","author":"DeSilva","year":"2001","journal-title":"AIDS"},{"key":"R30-10-20210213","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00044011-200323100-00002","article-title":"Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individuals.","volume":"23","author":"de Maat","year":"2003","journal-title":"Clin Drug Investig"},{"key":"R31-10-20210213","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.43.7.1815","article-title":"Effect of fluoxetine on pharmacokinetics of ritonavir.","volume":"43","author":"Ouellet","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-10-20210213","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.43.7.1815","article-title":"Ritonavir-fluoxetine interaction.","volume":"43","author":"Eralp Bellibas","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-10-20210213","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0149-2918(03)80076-0","article-title":"An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.","volume":"25","author":"Gutierrez","year":"2003","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"R34-10-20210213","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1520-6394(2000)12:1+<30::AID-DA4>3.0.CO;2-G","article-title":"Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.","volume":"12","author":"Ereshefsky","year":"2000","journal-title":"Depress Anxiety"},{"key":"R35-10-20210213","first-page":"62","article-title":"A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.","volume":"35","author":"Levin","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"R36-10-20210213","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0304-3959(95)00217-0","article-title":"The undertreatment of pain in ambulatory AIDS patients.","volume":"65","author":"Breitbart","year":"1996","journal-title":"Pain"},{"key":"R37-10-20210213","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.2146\/ajhp050006","article-title":"Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.","volume":"62","author":"Westanmo","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"R38-10-20210213","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1176\/appi.psy.44.2.120","article-title":"A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients.","volume":"44","author":"Currier","year":"2003","journal-title":"Psychosomatics"},{"key":"R39-10-20210213","first-page":"100","article-title":"Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.","volume":"29","author":"Hesse","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R40-10-20210213","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.clpt.6100027","article-title":"Lopinavir\/ritonavir reduces bupropion plasma concentrations in healthy subjects.","volume":"81","author":"Hogeland","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R41-10-20210213","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4088\/JCP.v60n0404","article-title":"Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazadone.","volume":"60","author":"Elliott","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R42-10-20210213","article-title":"The Top 100 Drug Interactions\u2014A Guide to Patient Management. 2007 Edition.","author":"Hansten","year":"2007"},{"key":"R43-10-20210213","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0091270003251864","article-title":"Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.","volume":"43","author":"Greenblatt","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R44-10-20210213","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00004714-200004000-00023","article-title":"Mirtazapine for depression in patients with human immunodeficiency virus.","volume":"20","author":"Elliott","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R45-10-20210213","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4088\/JCP.v61n0608","article-title":"Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial.","volume":"61","author":"Wagner","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R46-10-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2190\/16FH-9ECT-Y280-VV45","article-title":"Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine.","volume":"25","author":"Fernandez","year":"1995","journal-title":"Int J Psychiatry Med"},{"key":"R47-10-20210213","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3999(96)00366-2","article-title":"Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study.","volume":"42","author":"Wagner","year":"1997","journal-title":"J Psychosom Res"},{"key":"R48-10-20210213","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0163-8343(94)00062-I","article-title":"Testosterone replacement therapy in HIV illness.","volume":"17","author":"Rabkin","year":"1995","journal-title":"Gen Hosp Psychiatry"},{"key":"R49-10-20210213","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archpsyc.57.2.141","article-title":"A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms.","volume":"57","author":"Rabkin","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R50-10-20210213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.jcp.0000132442.35478.3c","article-title":"Testosterone versus fluoxetine for depression and fatigue in HIV\/AIDS: a placebo-controlled trial.","volume":"24","author":"Rabkin","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R51-10-20210213","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004714-199902000-00006","article-title":"Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism.","volume":"19","author":"Rabkin","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R52-10-20210213","first-page":"811","article-title":"Exercise as a mediator of psychological and nutritional effects of testosterone therapy in HIV+ men.","volume":"30","author":"Wagner","year":"1998","journal-title":"Med Sci Sports Exerc"},{"key":"R53-10-20210213","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/appi.ajp.163.1.59","article-title":"Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV\/AIDS.","volume":"163","author":"Rabkin","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R54-10-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(99)00036-0","article-title":"DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.","volume":"25","author":"Rabkin","year":"2000","journal-title":"Psychoneuroendocrinology"},{"key":"R55-10-20210213","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4088\/JCP.v65n1215","article-title":"Modafinil treatment for fatigue in HIV+ patients: a pilot study.","volume":"65","author":"Rabkin","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R56-10-20210213","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.ajp.161.1.3","article-title":"What is a \u201cmood stabilizer\u201d? An evidence-based response.","volume":"161","author":"Bauer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R57-10-20210213","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1099\/0022-1317-77-9-1993","article-title":"Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels.","volume":"77","author":"Moog","year":"1996","journal-title":"J Gen Virol"},{"key":"R58-10-20210213","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/070674370104600409","article-title":"The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes.","volume":"46","author":"Maggi","year":"2001","journal-title":"Can J Psychiatry"},{"key":"R59-10-20210213","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/13550280600981695","article-title":"Valproic acid does not affect markers of human immunodeficiency virus disease progression.","volume":"12","author":"Ances","year":"2006","journal-title":"J Neurovirol"},{"key":"R60-10-20210213","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.48.11.4328-4331.2004","article-title":"Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.","volume":"48","author":"DiCenzo","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R61-10-20210213","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1345\/aph.19211","article-title":"Carbamazepin-indinavir interaction causes antiretroviral therapy failure.","volume":"34","author":"Hugen","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R62-10-20210213","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003088-200140030-00005","article-title":"Delavirdine: clinical pharmacokinetics and drug interactions.","volume":"40","author":"Tran","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R63-10-20210213","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00002826-200007000-00009","article-title":"Protease inhibitor-induced carbamazepine toxicity.","volume":"23","author":"Berbel Garcia","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"R64-10-20210213","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/depr.3050010403","article-title":"Antidepressants and HIV infection: effect of lithium chloride and desipramine on HIV replication.","volume":"1","author":"Evans","year":"1993","journal-title":"Depression"},{"key":"R65-10-20210213","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/01.aids.0000244208.49123.1b","article-title":"Lithium improves HIV-associated neurocognitive impairment.","volume":"20","author":"Letendre","year":"2006","journal-title":"AIDS"},{"key":"R66-10-20210213","first-page":"119","article-title":"Effect of lithium carbonate in HIV-infected patients with immune dysfunction.","volume":"1","author":"Parenti","year":"1988","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R67-10-20210213","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.WNL.0000063304.88470.D9","article-title":"Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.","volume":"60","author":"Simpson","year":"2003","journal-title":"Neurology"},{"key":"R68-10-20210213","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","article-title":"Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects.","volume":"80","author":"van der Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R69-10-20210213","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00006842-200005000-00015","article-title":"Psychological effects of HAART: a 2-year study.","volume":"62","author":"Rabkin","year":"2000","journal-title":"Psychosom Med"},{"key":"R70-10-20210213","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00042560-200203010-00004","article-title":"Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.","volume":"29","author":"Fumaz","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R71-10-20210213","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1176\/ajp.148.11.1558","article-title":"Extrapyramidal symptoms due to dopamine blocking agents in patients with AIDS encephalopathy.","volume":"148","author":"Hriso","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R72-10-20210213","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000150539","article-title":"HIV dementia and the basal ganglia.","volume":"40","author":"Berger","year":"1997","journal-title":"Intervirology"},{"key":"R73-10-20210213","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0006-3223(97)00552-0","article-title":"Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.","volume":"44","author":"Meyer","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R74-10-20210213","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/ajp.151.2.237","article-title":"HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group.","volume":"151","author":"Sewell","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"11 Suppl","key":"R75-10-20210213","first-page":"1","article-title":"Work Group on HIV\/AIDS. American Psychiatric Association.","volume":"157","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R76-10-20210213","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1473-3099(07)70287-6","article-title":"HIV-associated dyslipidaemia: pathogenesis and treatment.","volume":"7","author":"Oh","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"5 Suppl 1","key":"R77-10-20210213","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","article-title":"Atypical antipsychotics and metabolic dysregulation: evaluating the risk\/benefit equation and improving the standard of care.","volume":"24","author":"Nasrallah","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R78-10-20210213","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J","article-title":"Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism.","volume":"14","author":"Lera","year":"1999","journal-title":"Mov Disord"},{"key":"R79-10-20210213","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3999(96)00373-X","article-title":"Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases.","volume":"42","author":"Singh","year":"1997","journal-title":"J Psychosom Res"},{"key":"R80-10-20210213","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00004714-200208000-00006","article-title":"Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.","volume":"22","author":"Penzak","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R81-10-20210213","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/archneur.1994.00540190069017","article-title":"Neuropsychological characterization of the AIDS dementia complex andrationalization of a test battery.","volume":"51","author":"Maruff","year":"1994","journal-title":"Arch Neurol"},{"key":"R82-10-20210213","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/00002030-199112000-00013","article-title":"Cognitive impairment in HIV infection.","volume":"5","author":"Krikorian","year":"1991","journal-title":"AIDS"},{"key":"R83-10-20210213","first-page":"112","article-title":"Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol.","volume":"88","author":"Hestad","year":"1993","journal-title":"Scand"},{"key":"R84-10-20210213","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archneur.1996.00550020059016","article-title":"Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection.","volume":"53","author":"Kieburtz","year":"1996","journal-title":"Arch Neurol"},{"key":"R85-10-20210213","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0006-3223(96)00014-5","article-title":"Successful zidovudine (AZT) treatment in a case of human immunodeficiency virus(HIV)-1-associated dementia complex.","volume":"39","author":"Sobanski","year":"1996","journal-title":"Biol Psychiatry"},{"key":"R86-10-20210213","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00126334-200405010-00003","article-title":"Highly active antiretroviral therapy improves neurocognitive functioning.","volume":"36","author":"Robertson","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R87-10-20210213","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1212\/WNL.56.2.257","article-title":"HIV-associated neurologic disease incidence changes: Multicenter AIDS cohort study, 1990\u20131998.","volume":"56","author":"Sacktor","year":"2001","journal-title":"Neurology"},{"key":"R88-10-20210213","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1148\/radiology.206.2.9457204","article-title":"Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy.","volume":"206","author":"Filippi","year":"1998","journal-title":"Radiology"},{"key":"R89-10-20210213","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1212\/WNL.53.4.782","article-title":"Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.","volume":"53","author":"Chang","year":"1999","journal-title":"Neurology"},{"key":"R90-10-20210213","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00042560-200109010-00004","article-title":"Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years.","volume":"28","author":"Tozzi","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R91-10-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.64.1.97","article-title":"An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.","volume":"64","author":"Sevigny","year":"2007","journal-title":"Arch Neurol"},{"key":"R92-10-20210213","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1523\/JNEUROSCI.1933-04.2004","article-title":"Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis.","volume":"24","author":"Anderson","year":"2004","journal-title":"J Neurosci"},{"key":"R93-10-20210213","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0306-4522(02)00925-9","article-title":"Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis.","volume":"118","author":"Anderson","year":"2003","journal-title":"Neuroscience"},{"key":"R95-10-20210213","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00126334-200501010-00021","article-title":"Could cholinesterase inhibitors and memantine alleviate HIV dementia?","volume":"38","author":"Alisky","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R96-10-20210213","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0010-440X(96)90023-1","article-title":"A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients.","volume":"37","author":"Wagner","year":"1996","journal-title":"Compr Psychiatry"},{"key":"R97-10-20210213","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1067\/mcp.2000.105757","article-title":"Alprazolam-ritonavir interaction: implications for product labeling.","volume":"67","author":"Greenblatt","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R98-10-20210213","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(99)05712-8","article-title":"Indinavir concentrations and St. John\u2019s wort.","volume":"355","author":"Piscitelli","year":"2000","journal-title":"Lancet"},{"key":"R99-10-20210213","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0006-3223(94)91166-5","article-title":"Cytokine production in major depressed patients before and after clomipramine treatment.","volume":"35","author":"Weizman","year":"1994","journal-title":"Biol Psychiatry"},{"key":"R100-10-20210213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000026555","article-title":"Antidepressants augment natural killer cell activity: in vivo and in vitro.","volume":"39","author":"Frank","year":"1999","journal-title":"Neuropsychobiology"},{"key":"R101-10-20210213","first-page":"331","article-title":"Triple diagnosis: dual diagnosis and HIV disease, Part 1.","volume":"13","author":"Douaihy","year":"2003","journal-title":"AIDS Read"},{"key":"R102-10-20210213","first-page":"375","article-title":"Triple diagnosis: dual diagnosis and HIV disease, part 2.","volume":"13","author":"Douaihy","year":"2003","journal-title":"AIDS Read"}],"container-title":["Psychosomatic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006842-200806000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:20Z","timestamp":1786035680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006842-200806000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/psy.0b013e3181777190","relation":{},"ISSN":["0033-3174"],"issn-type":[{"value":"0033-3174","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}